
    
      The study will be a 10 to 12-week study, including a 1 to 3-week screening Period, followed
      by a double-blind, randomized, placebo-controlled, parallel-group Treatment Period, and a
      1-week follow-up Period. Subjects eligible for the study will be randomized to receive either
      NYX-783 (4-weeks) or placebo (4 or 8-weeks).
    
  